Table 1. Demographic and Baseline Characteristics of Patients.
| Characteristic | Valuea (N = 125) |
|---|---|
| Age, median (range), y | 62.0 (27-84) |
| <65 | 74 (59.2) |
| ≥65 | 51 (40.8) |
| ECOG performance status | |
| 0 | 60 (48.0) |
| 1 | 65 (52.0) |
| Time since first diagnosis, median (range), y | 4.0 (0.8-24.3) |
| Time since diagnosis of metastatic disease, median (range), y | 2.4 (0.03-17.2) |
| No. of prior anticancer therapy lines for metastatic or locally advanced disease | |
| 0 | 5 (4.0) |
| 1 | 14 (11.2) |
| 2 | 25 (20.0) |
| 3 | 28 (22.4) |
| 4 | 22 (17.6) |
| ≥5 | 31 (24.8) |
| Median (range) | 3 (0-10) |
| Histologic type | |
| Serous | 93 (74.4) |
| Mucinous | 4 (3.2) |
| Endometrioid | 3 (2.4) |
| Clear cell | 2 (1.6) |
| Transitional cell | 1 (0.8) |
| Other | 3 (2.4) |
| Uncoded or missing | 19 (15.2) |
| CA125 level, IU/mL | |
| <35 | 8 (6.4) |
| 35-70 | 13 (10.4) |
| >70 | 52 (41.6) |
| Unavailable | 52 (41.6) |
| BRCA mutation status | |
| Negative | 38 (30.4) |
| Positiveb | 8 (6.4) |
| Unknown | 79 (63.2) |
Abbreviations: CA125, cancer antigen 125; ECOG, Eastern Cooperative Oncology Group.
SI conversion factor: To convert CA125 to kilounits per liter, multiply by 1.0.
a
Data are presented as number (percentage) of patients unless otherwise indicated.
b
Deleterious mutation or mutation of uncertain significance.